Heights Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.9M Sell
648,083
-1,917
-0.3% -$20.3K 1.59% 9
2026
Q1
$6.83M Hold
650,000
1.9% 8
2025
Q4
$6.74M Hold
650,000
2.42% 5
2025
Q3
$6.68M Hold
650,000
1.9% 10
2025
Q2
$6.63M Buy
+650,000
New +$6.57M 1.77% 15

Other funds holding DMAA

Heights Capital Management's DMAA Position: Q2 2026 in Review

Heights Capital Management reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 0.29% in Q2 2026, selling an estimated $20.3K and leaving 648,083 shares worth $6.9M. The position accounts for 1.59% of the portfolio, ranked #9.

Heights Capital Management first reported a position in DMAA in Q2 2025 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Heights Capital Management held 648,083 shares of Drugs Made In America Acquisition Corp worth $6.9M as of Q2 2026.
  • Heights Capital Management sold 1,917 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $20.3K.
  • Drugs Made In America Acquisition Corp made up 1.59% of Heights Capital Management's portfolio in Q2 2026, its #9 holding.
  • Heights Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and has held it in 5 quarters since.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.